Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 12/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.42 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5500310 | 0.79 | SIGMAR1 (0.49) | SIGMAR1NPC1RAB9ACYP1A2CYP3A4 | |
| SCHEMBL6008739 | 0.73 | SIGMAR1 (0.49) | SIGMAR1NPC1RAB9ACYP1A2CYP3A4 | |
| SCHEMBL15819038 | 0.72 | SIGMAR1 (0.54) | SIGMAR1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL27894265 | 0.68 | SIGMAR1 (0.68) | SIGMAR1NPC1RAB9ACYP1A2CYP3A4 | |
| SCHEMBL3847752 | 0.68 | SIGMAR1 (0.68) | SIGMAR1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL29059547 | 0.68 | SIGMAR1 (0.81) | SIGMAR1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL8986800 | 0.67 | NPC1 (0.62) | SIGMAR1NPC1RAB9ACYP1A2CYP3A4 | |
| SCHEMBL8986798 | 0.67 | NPC1 (0.62) | SIGMAR1NPC1RAB9ACYP1A2CYP3A4 | |
| SCHEMBL4462033 | 0.67 | NPC1 (0.67) | SIGMAR1NPC1RAB9ATAAR1SLC18A2 | |
| Methamphetamine SCHEMBL4424041 | 0.67 | SIGMAR1 (0.70) | SIGMAR1NPC1RAB9ACYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828111-A2 | METHODS AND FLUORINATED COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | Neurochem (International) Limited (CH) | 2007-09-05 | — | — | EP | disclosed |
| US-20060183800-A1 | Methods and fluorinated compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2006-08-17 | — | — | US | disclosed |
| WO-2006059252-A2 | METHODS AND FLUORINATED COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183800-A1 | Methods and fluorinated compositions for treating amyloid-related diseases | APP, PSEN1, TTR | SIGMAR1 3705/4885NPC1 37/4885RAB9A 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.